Home/Pipeline/E-602

E-602

Autoimmune Diseases

IND-EnablingActive

Key Facts

Indication

Autoimmune Diseases

Phase

IND-Enabling

Status

Active

Company

Palleon Pharmaceuticals

About Palleon Pharmaceuticals

Palleon Pharmaceuticals is at the forefront of glycobiology-based drug discovery, developing first-in-class therapies that degrade cell surface sialoglycans to treat cancer and autoimmune diseases. Its core technology, the EAGLE platform, fuses human sialidase enzymes with targeting antibodies to selectively remove immunosuppressive sugar molecules from diseased cells, rendering them vulnerable to immune attack. The company has advanced programs in both oncology (E-688) and immunology (E-602), supported by a strategic collaboration with Henlius. Palleon represents a private, preclinical-stage biotech targeting a significant new frontier in immuno-oncology and inflammation.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
Humira (Adalimumab) Biosimilar	NeuClone	Early Preclinical	Active
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Gavocabtagene autoleucel	astellas	Phase 1/2	Active
TYK-101	TYK Medicines	Phase 1	Active
HCB206	HanchorBio	Preclinical	Active
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active